Treating Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women
with FDA approved drug can be a great solution in near future! Just a couple of
days ago, in 17 February 2015, Sprout Pharmaceuticals authority announced that
the company has resubmitted an application to the FDA for approval of a
non-hormonal pill “Flibanserin” designed for treatment of Hypoactive Sexual
Desire Disorder (HSDD) in premenopausal women. Flibanserin, if FDA approved,
will be the first treatment for HSDD. The CEO of Sprout Pharmaceuticals, Cindy
Whitehead said, “This NDA re-submission marks the completion of the additional
clinical studies requested by FDA”. Cindy is also expecting the approval will
be in this year.
